Study aim
isodose
RECURRENCE, SCAR
This study aims to demonstrate the safety of escalating the usually employed dose from 25 Gy prescribed to the 65–90% target volume encompassing isodose to a maximum of 32.5 Gy prescribed to the 65–90% with the ultimate goal of decreasing long-term sVA recurrence rates through homogeneous scar formation.